Evaluation of systemic mRNA/peptide-based nanoparticle vaccines in melanoma tumor models (Q04)

• Subject Area: Immunology
• Term: since 2017
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 213555243

In TP Q4, human-relevant animal models and in vitro systems as alternatives to animal models, which are of use for the entire SFB, will be further developed and characterized by investigating the genetic variability and neoantigen expression in spontaneously developing murine melanomas and by establishing methods for standardized procedures of immunotherapy experiments in spontaneous tumor models. Furthermore, animal model alternatives, such as tumor organoids will further be improved to analyse changes in the tumor microenvironment and to investigate the effects of NP on the tumor-specific immune response.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1066: Nano-Dimensional Polymer Therapeutics for Tumour Therapy
• Applicant Institution: Johannes Gutenberg-Universität Mainz
• Project Heads: Dr. Mustafa Diken, Ph.D.; Professor Dr. Hansjörg Schild